|
TCS bags clinical trial data contract from Novo Nordisk
Business Standard
December 19, 2005
Tata
Consultancy Services (TCS) has bagged a clinical trial
data management contract from Danish pharmaceutical
major, Novo Nordisk, even as it has initiated discussion
for similar contracts from global pharma majors. Under
the agreement, the Tata group company will conduct offshore
clinical operation services for Novo Nordisk in India
and offer a slew of data management services. The size
of the deal could not be ascertained.
Industry sources said this could be a multi-million
dollar deal over a period of time, as the global outsourcing
of clinical trial management is estimated at around
$1 billion over the next five-year period. Confirming
the news, executive vice-president and head (Global
Life Sciences and Healthcare Practice) J Rajgopal said,
"This could be one of the first outsourcing deals,
in the clinical trial-data management space, for an
Indian company".
He added: "The deal is strategic in nature, as
it gives our company an opportunity to leverage our
domain capability and provide our products, solutions
and services across the pharma value chain." He,
however, did not divulge the size of the deal. TCS plans
to implement offshore clinical operations services from
its Mumbai centre and offer a slew of data management
services, such as designing, capturing and coding of
trial-data, gathered by Novo Nordisk from across the
world.
Earlier this year, TCS had entered into an agreement
with Congenia, a biotechnology start-up promoted by
Italy's Genextra SpA group, to provide advanced fragment-based
lead optimisation solutions for drug discovery. TCS
will work on "P66" - a target protein identified
by Congenia as a key protein involved in several age-related
diseases - and develop optimised drug leads based on
this. TCS is focussing on the life-science sector, as
an engine of growth and is expecting to post revenues
of 50 per cent growth over the next few years.
TCS is also close to tying-up with other pharma majors
across the world for similar kind of deals. However,
Rajgopal did not divulge the name of the companies,
the company was in talks with.
|
|